BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

310 related articles for article (PubMed ID: 28524246)

  • 1. Combined PET-CT and axillary lymph node marking with radioactive iodine seeds (MARI procedure) for tailored axillary treatment in node-positive breast cancer after neoadjuvant therapy.
    Koolen BB; Donker M; Straver ME; van der Noordaa MEM; Rutgers EJT; Valdés Olmos RA; Vrancken Peeters MJTFD
    Br J Surg; 2017 Aug; 104(9):1188-1196. PubMed ID: 28524246
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Major Reduction in Axillary Lymph Node Dissections After Neoadjuvant Systemic Therapy for Node-Positive Breast Cancer by combining PET/CT and the MARI Procedure.
    van der Noordaa MEM; van Duijnhoven FH; Straver ME; Groen EJ; Stokkel M; Loo CE; Elkhuizen PHM; Russell NS; Vrancken Peeters MTFD
    Ann Surg Oncol; 2018 Jun; 25(6):1512-1520. PubMed ID: 29511992
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Marking axillary lymph nodes with radioactive iodine seeds for axillary staging after neoadjuvant systemic treatment in breast cancer patients: the MARI procedure.
    Donker M; Straver ME; Wesseling J; Loo CE; Schot M; Drukker CA; van Tinteren H; Sonke GS; Rutgers EJ; Vrancken Peeters MJ
    Ann Surg; 2015 Feb; 261(2):378-82. PubMed ID: 24743607
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Three-year follow-up of de-escalated axillary treatment after neoadjuvant systemic therapy in clinically node-positive breast cancer: the MARI-protocol.
    van Loevezijn AA; van der Noordaa MEM; Stokkel MPM; van Werkhoven ED; Groen EJ; Loo CE; Elkhuizen PHM; Sonke GS; Russell NS; van Duijnhoven FH; Vrancken Peeters MTFD
    Breast Cancer Res Treat; 2022 May; 193(1):37-48. PubMed ID: 35239072
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Diagnostic Accuracy of Radioactive Iodine Seed Placement in the Axilla With Sentinel Lymph Node Biopsy After Neoadjuvant Chemotherapy in Node-Positive Breast Cancer.
    Simons JM; van Nijnatten TJA; van der Pol CC; van Diest PJ; Jager A; van Klaveren D; Kam BLR; Lobbes MBI; de Boer M; Verhoef C; Sars PRA; Heijmans HJ; van Haaren ERM; Vles WJ; Contant CME; Menke-Pluijmers MBE; Smit LHM; Kelder W; Boskamp M; Koppert LB; Luiten EJT; Smidt ML
    JAMA Surg; 2022 Nov; 157(11):991-999. PubMed ID: 36069889
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A Novel Less-invasive Approach for Axillary Staging After Neoadjuvant Chemotherapy in Patients With Axillary Node-positive Breast Cancer by Combining Radioactive Iodine Seed Localization in the Axilla With the Sentinel Node Procedure (RISAS): A Dutch Prospective Multicenter Validation Study.
    van Nijnatten TJA; Simons JM; Smidt ML; van der Pol CC; van Diest PJ; Jager A; van Klaveren D; Kam BLR; Lobbes MBI; de Boer M; Verhoef K; Koppert LB; Luiten EJT
    Clin Breast Cancer; 2017 Aug; 17(5):399-402. PubMed ID: 28487053
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Marking the axilla with radioactive iodine seeds (MARI procedure) may reduce the need for axillary dissection after neoadjuvant chemotherapy for breast cancer.
    Straver ME; Loo CE; Alderliesten T; Rutgers EJ; Vrancken Peeters MT
    Br J Surg; 2010 Aug; 97(8):1226-31. PubMed ID: 20602508
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Diagnostic Accuracy of Different Surgical Procedures for Axillary Staging After Neoadjuvant Systemic Therapy in Node-positive Breast Cancer: A Systematic Review and Meta-analysis.
    Simons JM; van Nijnatten TJA; van der Pol CC; Luiten EJT; Koppert LB; Smidt ML
    Ann Surg; 2019 Mar; 269(3):432-442. PubMed ID: 30312200
    [TBL] [Abstract][Full Text] [Related]  

  • 9. This house believes that: MARI/TAD is better than sentinel node biopsy after PST for cN+ patients.
    van Hemert AKE; van Duijnhoven FH; Vrancken Peeters MTFD
    Breast; 2023 Oct; 71():89-95. PubMed ID: 37562108
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Early assessment of axillary response with ¹⁸F-FDG PET/CT during neoadjuvant chemotherapy in stage II-III breast cancer: implications for surgical management of the axilla.
    Koolen BB; Valdés Olmos RA; Wesseling J; Vogel WV; Vincent AD; Gilhuijs KG; Rodenhuis S; Rutgers EJ; Vrancken Peeters MJ
    Ann Surg Oncol; 2013 Jul; 20(7):2227-35. PubMed ID: 23456316
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Fluorodeoxyglucose positron emission tomography with sentinel lymph node biopsy for evaluation of axillary involvement in breast cancer.
    Gil-Rendo A; Zornoza G; García-Velloso MJ; Regueira FM; Beorlegui C; Cervera M
    Br J Surg; 2006 Jun; 93(6):707-12. PubMed ID: 16622900
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Axillary lymph node staging in breast cancer by 2-fluoro-2-deoxy-D-glucose-positron emission tomography: clinical evaluation and alternative management.
    Greco M; Crippa F; Agresti R; Seregni E; Gerali A; Giovanazzi R; Micheli A; Asero S; Ferraris C; Gennaro M; Bombardieri E; Cascinelli N
    J Natl Cancer Inst; 2001 Apr; 93(8):630-5. PubMed ID: 11309439
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Diagnostic accuracy of de-escalated surgical procedure in axilla for node-positive breast cancer patients treated with neoadjuvant systemic therapy: A systematic review and meta-analysis.
    Song YX; Xu Z; Liang MX; Liu Z; Hou JC; Chen X; Xu D; Fei YJ; Tang JH
    Cancer Med; 2022 Nov; 11(22):4085-4103. PubMed ID: 35502768
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Axillary Management of Stage II/III Breast Cancer in Patients Treated with Neoadjuvant Systemic Therapy: Results of CALGB 40601 (HER2-Positive) and CALGB 40603 (Triple-Negative).
    Ollila DW; Cirrincione CT; Berry DA; Carey LA; Sikov WM; Hudis CA; Winer EP; Golshan M
    J Am Coll Surg; 2017 Apr; 224(4):688-694. PubMed ID: 28089784
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Locoregional lymph node involvement on 18F-FDG PET/CT in breast cancer patients scheduled for neoadjuvant chemotherapy.
    Koolen BB; Valdés Olmos RA; Elkhuizen PH; Vogel WV; Vrancken Peeters MJ; Rodenhuis S; Rutgers EJ
    Breast Cancer Res Treat; 2012 Aug; 135(1):231-40. PubMed ID: 22872522
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Lymphoscintigraphy in breast cancer patients after neoadjuvant chemotherapy. Diagnostic value and the work-up of sentinel node negative patients.
    Dalus K; Reitsamer R; Holzmannhofer J; Rendl G; Pirich C; Kronberger C; Rettenbacher L
    Nuklearmedizin; 2011; 50(1):33-8. PubMed ID: 21336417
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Improved Axillary Evaluation Following Neoadjuvant Therapy for Patients With Node-Positive Breast Cancer Using Selective Evaluation of Clipped Nodes: Implementation of Targeted Axillary Dissection.
    Caudle AS; Yang WT; Krishnamurthy S; Mittendorf EA; Black DM; Gilcrease MZ; Bedrosian I; Hobbs BP; DeSnyder SM; Hwang RF; Adrada BE; Shaitelman SF; Chavez-MacGregor M; Smith BD; Candelaria RP; Babiera GV; Dogan BE; Santiago L; Hunt KK; Kuerer HM
    J Clin Oncol; 2016 Apr; 34(10):1072-8. PubMed ID: 26811528
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A comparative study on the value of FDG-PET and sentinel node biopsy to identify occult axillary metastases.
    Veronesi U; De Cicco C; Galimberti VE; Fernandez JR; Rotmensz N; Viale G; Spano G; Luini A; Intra M; Veronesi P; Berrettini A; Paganelli G
    Ann Oncol; 2007 Mar; 18(3):473-8. PubMed ID: 17164229
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Axillary lymph node response to neoadjuvant systemic therapy with dedicated axillary hybrid
    de Mooij CM; Samiei S; Mitea C; Lobbes MBI; Kooreman LFS; Heuts EM; Beets-Tan RGH; van Nijnatten TJA; Smidt ML
    Clin Radiol; 2022 Oct; 77(10):e732-e740. PubMed ID: 35850866
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Management of the axilla after neoadjuvant chemotherapy for clinically node positive breast cancer: A nationwide survey study in The Netherlands.
    Vugts G; Maaskant-Braat AJ; de Roos WK; Voogd AC; Nieuwenhuijzen GA
    Eur J Surg Oncol; 2016 Jul; 42(7):956-64. PubMed ID: 27107791
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.